| Related Articles |
Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
Expert Rev Neurother. 2017 Sep;17(9):883-894
Authors: Salem H, Pigott T, Zhang XY, Zeni CP, Teixeira AL
Abstract
INTRODUCTION: Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a complex pathophysiological basis. A significant percentage of patients does not receive correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore, there is a critical need for prompt recognition, implementation of efficacious treatment regimens and long-term follow up of patients with TD. Areas covered: The current paper provides an overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for TD. Expert commentary: Despite considerable research efforts, TD remains a challenge in the treatment of psychosis as the available strategies remain sub-optimal. The best scenario will always be the prophylaxis or prevention of TD, which entails limiting the use of antipsychotics.
PMID: 28750568 [PubMed – indexed for MEDLINE]
via https://www.ncbi.nlm.nih.gov/pubmed/28750568?dopt=Abstract
